EICHORCondition: Cutaneous Melanoma · Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck · Sponsor: Genocea Biosciences, Inc.
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A proprietary tool developed by Genocea, called ATLAS™ (Antigen Lead Acquisition System) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T cells. ATLAS-identified neoantigens will then be incorporated into a patient's personalized vaccine in the form of synthetic long peptides (SLPs).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| John Wayne Cancer Institute - Providence Saint John's Health Center | Santa Monica, California, United States | — |
| University of Colorado, Anschutz Cancer Pavilion | Aurora, Colorado, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | — |
| Columbia University Medical Center - Herbert Irving Pavilion | New York, New York, United States | — |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| The Sarah Cannon Research Institute | Nashville, Tennessee, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03633110